Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Curletta

Interventional Pain Medicine Gilbert, AZ Medical Doctor

NPI 1952378804 CMS profile 43512

3645 S Rome St Ste 216, Ste A8, Gilbert, AZ 85297

Open in the dashboard

General payments

$8,496

428 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Curletta of Gilbert, AZ is reported in the CMS Open Payments database as having received $8,496 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2024 General $481 14
2023 General $927 49
2022 General $2,286 116
2021 General $1,468 50
2020 General $569 32
2019 General $2,740 166

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Curletta
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Joseph Curletta were reported at $24. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Joseph Curletta Interventional Pain Medicine median Middle half National median
2019 $2,740 $684 $216–$2,079 $163
2020 $569 $382 $122–$1,109 $114
2021 $1,468 $552 $167–$1,554 $132
2022 $2,286 $605 $187–$1,924 $149
2023 $927 $671 $195–$1,915 $160
2024 $481 $684 $206–$1,837 $164
2025 $24 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,299 73 payments
  2. Abbott Laboratories $837 45 payments
  3. Merz North America, Inc. $670 11 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $550 40 payments
  5. Nevro Corp. $478 12 payments
  6. Medtronic USA, Inc. $470 7 payments
  7. Scilex Pharmaceuticals Inc. $383 23 payments
  8. Collegium Pharmaceutical, Inc. $382 48 payments
  9. TerSera Therapeutics LLC $379 14 payments
  10. GRT US Holding, Inc. $264 12 payments
  11. Other $2,784 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,323 424 payments
  2. Education $173 4 payments
Products named General payments · program years 2019–2025
  1. GENERAL PAIN MANAGEMENT $701 35 payments
  2. PROCLAIM $593 37 payments
  3. RELISTOR $506 37 payments
  4. General - Pain Management $421 19 payments
  5. INTELLIS $338 5 payments
  6. XTAMPZA $322 46 payments
  7. Qutenza $322 14 payments
  8. Omnia $313 10 payments
  9. Xeomin $309 4 payments
  10. PRIALT $239 9 payments
  11. Other $4,496 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

768

Median for Interventional Pain Management: 1,220

Drug cost

$26,988

Median for Interventional Pain Management: $39,344

Branded share of claims

32.3%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 13 $8,120
Morphine Sulfate Er Morphine Sulfate Brand 87 $3,191
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 95 $2,751
Oxycodone Hcl Generic 134 $2,262
Fentanyl Generic 16 $2,178
Gabapentin Generic 73 $1,368
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 53 $1,337
Pregabalin Generic 48 $1,236
Diclofenac Sodium Generic 16 $936
Baclofen Generic 44 $801

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$15,638

Of which drugs: $148

Medicare patients

104

Average age 72

Services billed

797

71 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 37%
Diabetes 35%
Ischemic heart disease 23%
Chronic kidney disease 23%
Osteoporosis 21%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 16 208 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GABLOFEN
  • Piramal Critical Care $25
$25 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $14
$14 — —
MITIGO
  • Piramal Critical Care $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record